Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 21Recruiting 9Terminated 7Unknown 4Active not recruiting 4Withdrawn 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 3Lymphoma 1Gliosarcoma 1

Interventions

Temozolomide 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Radiotherapy 4Radiation 4Lomustine 3Carmustine 3pembrolizumab 2dexamethasone acetate 2atezolizumab 2TIC10 compound 2Surgical Procedures, Operative 2Sunitinib 2Standard of Care 2Specimen Handling 2Sorafenib 2Radiosurgery 2Irinotecan 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 2Axitinib 2Aminolevulinic Acid 2vocimagene amiretrorepvec 1tandutinib 1poly ICLC 1pazopanib 1niraparib 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Glioblastoma × Lomustine × Clear all
NCT05304663 2024-04-08

GLIOASTRA

Philogen S.p.A.

Phase 1 Withdrawn
CNS

Glioblastoma

NCT05410301 2023-04-21

Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

University of Iowa

Phase NA Withdrawn
CNS

Glioblastoma

NCT05017610 2022-12-02

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Emory University

Phase EARLY_PHASE1 Withdrawn
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡